- Home
- ENTX vs CODA Comparison
ENTX vs CODA Comparison
Compare ENTX & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENTX | CODA |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 98.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ENTX | CODA |
|---|---|---|
| Price | $1.88 | $9.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 85.0K | 48.5K |
| Earning Date | 11-14-2025 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.09 |
| EPS | N/A | ★ 0.30 |
| Revenue | $124,000.00 | ★ $24,347,217.00 |
| Revenue This Year | N/A | $30.82 |
| Revenue Next Year | N/A | $20.84 |
| P/E Ratio | ★ N/A | $31.27 |
| Revenue Growth | 25.25 | ★ 29.34 |
| 52 Week Low | $1.50 | $5.76 |
| 52 Week High | $3.22 | $10.54 |
Technical Indicators
Market Signals| Indicator | ENTX | CODA |
|---|---|---|
| Relative Strength Index (RSI) | 27.62 | 61.17 |
| Support Level | $2.07 | $8.79 |
| Resistance Level | $2.22 | $9.58 |
| Average True Range (ATR) | 0.16 | 0.43 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 0.00 | 90.23 |
Price Performance
Historical ComparisonAbout ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.